A Phase II/III, Randomized, Open-Label, Active Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Efalizumab Compared With Cyclosporine, Both in Combination With Mycophenolate Mofetil and Corticosteroids, As an Immunosuppressant Regimen in De Novo Renal Transplantation
Withdrawn prior to enrolment
Phase of Trial: Phase II/III
Latest Information Update: 27 Jun 2017
At a glance
- Drugs Efalizumab (Primary) ; Basiliximab; Ciclosporin; Corticosteroids; Mycophenolate mofetil
- Indications Renal transplant rejection
- Focus Therapeutic Use
- Sponsors Genentech
- 12 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 25 Aug 2008 New trial record.